Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid
Discontinued Product
(RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid (Cat. No. 0335) has been withdrawn from sale for commercial reasons.
Description: Group III mGlu agonist. Analogue of L-AP4
Biological Activity
L-AP4 analogue, active at group III mGlu receptors.
Technical Data
| M. Wt | 207.13 |
| Storage | Store at RT |
| CAS Number | 140480-88-2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References
References are publications that support the biological activity of the product.
Allan et al (1990) Synthesis and activity of a potent NMDA agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. J.Med.Chem. 33 2905 PMID: 2145435
Peterson et al (1992) Activity of the conformationally rigid 2-amino-4-phosphonobutanoic acid (AP4) analogue (RS)-1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid on evoked responses in the perforant pathway of the rat hippocampus. Brain Res. 571 162 PMID: 1611490
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group III Receptor Agonists
Keywords: (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid, (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid supplier, Glutamate, (Metabotropic), Group, III, Receptors, 0335, Tocris Bioscience
Citations for (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid.
Reviews for (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid
There are currently no reviews for this product. Be the first to review (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid and earn rewards!
Have you used (RS)-1-Amino-3-(phosphonomethylene)cyclobutanecarboxylic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.